about
Vivax malaria in Mauritania includes infection of a Duffy-negative individualAssessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure.Tetracyclines in malariaAntibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria?Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial useSurveillance of travellers: an additional tool for tracking antimalarial drug resistance in endemic countriesInhibition of efflux of quinolines as new therapeutic strategy in malaria.A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms.Antimalarial drug use in general populations of tropical Africa.High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool.Atypical aetiology of a conjugal fever: autochthonous airport malaria between Paris and French Riviera: a case report.Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.The end of a dogma: the safety of doxycycline use in young children for malaria treatment.Determinants of compliance with malaria chemoprophylaxis among French soldiers during missions in inter-tropical AfricaIn vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum.Plasmodium falciparum proteome changes in response to doxycycline treatment.In vitro potentiation of antibiotic activities by a catecholate iron chelator against chloroquine-resistant Plasmodium falciparum.Malaria transmission and insecticide resistance of Anopheles gambiae in Libreville and Port-Gentil, Gabon.In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter geneUse of the atmospheric generators for capnophilic bacteria Genbag-CO2 for the evaluation of in vitro Plasmodium falciparum susceptibility to standard anti-malarial drugs.Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisininMultinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline.Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the CongoLimited polymorphisms in k13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012-2013Metal-chloroquine derivatives as possible anti-malarial drugs: evaluation of anti-malarial activity and mode of action.Artesunate tolerance in transgenic Plasmodium falciparum parasites overexpressing a tryptophan-rich protein.Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine.Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013-2014 malaria season.Dihydroethanoanthracene derivatives as in vitro malarial chloroquine resistance reversal agentsDeterminants of compliance with anti-vectorial protective measures among non-immune travellers during missions to tropical Africa.Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East AsiaIn vitro susceptibility to pyrimethamine of DHFR I164L single mutant Plasmodium falciparumEx vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugsDifferential association of Plasmodium falciparum Na+/H+ exchanger polymorphism and quinine responses in field- and culture-adapted isolates of Plasmodium falciparum.Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.Influence of oxygen on asexual blood cycle and susceptibility of Plasmodium falciparum to chloroquine: requirement of a standardized in vitro assayGenetic structure of Plasmodium falciparum and elimination of malaria, Comoros archipelago.Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.Molecular Markers and In Vitro Susceptibility to Doxycycline in Plasmodium falciparum Isolates from Thailand.Malaria epidemic and drug resistance, Djibouti
P50
Q21034116-3C333BD7-421C-4F4E-9113-6B69A069CA66Q25257654-D7B33FD3-8258-412E-AF39-A5AD823C1131Q26778176-CDD35EB3-BE32-4627-9359-EC3AE0870691Q28076750-C70BC8DF-451F-4C2E-B69E-F060098D553BQ28469104-77400BD2-3FC0-4510-9768-8307C02355C7Q28534753-52CDBBB3-2883-4C89-B425-D4DB69BB35ADQ30369381-9ADC6B55-4BEB-470C-A715-FEF48B52753AQ30379780-9A217C07-6CF5-4AFE-8448-FA74BC0913EBQ30482961-CF37D159-2A13-4647-8367-21E62F51165DQ30619647-66FA336E-3E70-4FF9-8EE3-B7462E22ED8CQ33385921-5140AD46-4C81-47E7-8967-E1DB5129494CQ33515839-FC410C63-0988-4A15-B0E9-BCAC0218D3E5Q33560396-A57A829B-9D46-457C-A09C-8C56B18D3C6AQ33690072-6A355A53-1BB2-483E-AB06-63492F3B4DFAQ33712676-8D6B9FA9-A726-48C7-AF91-C1F023F61D30Q33934205-12090D49-B884-4D23-A58D-47D0BE397DD0Q34104791-403736FE-1859-404C-93EF-88AE3F9A37BDQ34372461-60097C42-0EFD-421A-BFB9-5AE37607799BQ34478084-1DEBE928-F128-472C-A689-1C3BAB153576Q34541163-C48427CC-F9A7-4540-903B-B70659238488Q34597550-87722538-47AC-4A50-A1B6-4E713A4FDACAQ34601191-1027EA5D-B8E0-4E1F-A737-97EAD1C90662Q34719926-FE036850-878A-4D1C-89AA-C6EBEAAF3157Q34891749-02980DB5-9FE7-4812-B3FC-0F1933F76C6EQ34897244-61858DC8-AA0F-4D11-B7B1-0AEE340A6E89Q35004948-501AB364-C8BD-423D-83AD-9570FC1E11F6Q35068138-A4ED1B87-3EF5-4FF6-BC1F-A4E545B89697Q35101288-7C363860-2A19-4C17-BAF3-69A5E58F3930Q35125967-0BC393F1-5A6D-4FA0-BBA4-940BA0551A29Q35221889-1684A458-6FBA-422F-9FA7-AE5E16687B39Q35257668-0F36BDA0-4DF4-4503-B6B5-191465C9BB21Q35338819-3397D192-22BA-4405-B4A9-6CD908AC3575Q35533577-38BDB7A2-849E-43C1-90E5-F9B3C0DD7C77Q35598582-0DABC3C4-4133-40B2-AF26-005476C0D0C2Q35753471-5870C59E-CE3F-43CE-980A-AB7F19285004Q35757486-80C3A1D5-5AEF-4391-A6CD-41895D9835FCQ35804979-6F462419-333C-44EC-95B0-991322BA0B53Q35834198-779384CA-8734-4124-875E-A5FF5722AB5DQ35860167-497FA95A-88D4-49E1-A951-996206A3FD60Q35873309-725F2305-5BCA-46A7-839D-27877B11A6AB
P50
name
Bruno Pradines
@ast
Bruno Pradines
@en
Bruno Pradines
@es
Bruno Pradines
@nl
type
label
Bruno Pradines
@ast
Bruno Pradines
@en
Bruno Pradines
@es
Bruno Pradines
@nl
prefLabel
Bruno Pradines
@ast
Bruno Pradines
@en
Bruno Pradines
@es
Bruno Pradines
@nl